54274 Federal Register / Vol. 72, No. 184 / Monday, September 24, 2007 / Notices 

Licensing Contact: Chekesha S. 

Clingman, Ph.D.; 301/435–5018; 

clingmac@mail.nih.gov 

Collaborative Research Opportunity: 

The NIBIB/IR/Positron Emission 

Tomography Radiochemistry Group and 

the NIAID Biostatistic Research Branch 

are seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize a 

Fluorine-18 radiolabeled analog of 

tenofovir. Please contact Peter Moy 

(NIBIB); 301/496–9270; 

moype@mail.nih.gov for more 

information. 

Dated: September 17, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–18798 Filed 9–21–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the 

contracted proposals, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Heart Study Research Project. 

Date: October 18, 2007. 

Time: 9 a.m. to 1 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hilton Crystal City, 2399 Jefferson 

Davis Hwy, Arlington, VA 22202. 

Contact Person: Holly Patton, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7188, Bethesda, MD 20892–7924, 301–435–

0280, pattonh@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HSS) 

Dated: September 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4708 Filed 09–21–07; 8:45 am] 

BILLING CODE 4140–07–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Asthma and Allergic 

Diseases Cooperative Research Centers. 

Date: October 16–18, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Quirijn Vos, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, NIAID/NIH/DHHS, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892, (301) 451–2666, qvos@niaid.nih.gov. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group; Microbiology and Infectious Diseases 

B Subcommittee. 

Date: October 17, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: North Bethesda Marriott, 5701 

Marinelli Road, Bethesda, MD 20852. 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/ 

NIAID, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892, (301) 496–3528, 

gm12w@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Virology Program Project 

Application. 

Date: October 18, 2007. 

Time: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

1202, Bethesda, MD 20817 (Telephone 

Conference Call). 

Contact Person: Gary S. Madonna, PhD, 

Scientific Review Administrator, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/ 

NIAID, 6700B Rockledge Drive, Bethesda, 

MD 20892, (301) 496–3528, gm12w@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 17, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4710 Filed 9–21–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Public Teleconference Regarding 

Licensing and Collaborative Research 

Opportunities for: Novel Ligands for 

Diagnostic Imaging and 

Radioimmunotherapy; Dr. Martin 

Brechbiel et al. (NCI) 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice 

Technology Summary 

The technology describes the 

composition of several 1,4,7,10- 

tetraazacyclododecane-1,4,7,10- 

tetraacetic acid (DOTA) and 

diethylenetriaminepentaacetic acid 

(DTPA) compounds, their synthesis, 

metal complexes, conjugates, and their 

application in diagnostic imaging and 

radioimmunotherapy. 

Technology Description 

Monoclonal antibodies (mAbs) have 

been employed as targeting 

biomolecules for the delivery of 

radionuclides into tumor cells in 

radioimmunotherapy (RIT). Numerous 

clinical trials have been performed to 

validate this modality of cancer therapy. 

While one critical variable that 

influences the effectiveness of RIT is the 

choice of the radionuclide and its 


rfrederick on PROD1PC67 with NOTICES